Clinical Trial: Study of BB-025, Alone and After BB-031, in Healthy Volunteers

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07202663) titled 'Study of BB-025, Alone and After BB-031, in Healthy Volunteers' on Sept. 24.

Brief Summary: The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent.

In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms.

In the se...